Silicon Laboratories (SLAB) Financials

$216.81 +0.35 (+0.16%)

As of 10:02 AM Eastern

Annual Income Statements for Silicon Laboratories

This table shows Silicon Laboratories' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	1/2/2016	12/31/2016	12/30/2017	12/29/2018	12/28/2019	1/2/2021	1/1/2022	12/31/2022	12/30/2023	12/28/2024	1/3/2026
Net Income / (Loss) Attributable to Common Shareholders	30	61	47	84	19	13	2,117	91	-35	-191	-65
Consolidated Net Income / (Loss)	30	61	47	84	19	13	2,117	91	-35	-191	-65
Net Income / (Loss) Continuing Operations	30	61	47	84	-103	-115	-58	91	-35	-191	-65
Total Pre-Tax Income	30	64	77	72	-96	-132	-58	126	-11	-155	-58
Total Operating Income	32	66	85	85	-89	-107	-33	119	-24	-165	-71
Total Gross Profit	381	422	454	521	280	295	425	643	461	312	457
Total Revenue	645	698	769	868	474	511	721	1,024	782	584	785
Operating Revenue	645	698	769	868	474	511	721	1,024	782	584	785
Total Cost of Revenue	264	276	315	347	194	216	295	382	322	272	328
Operating Cost of Revenue	264	276	315	347	194	216	295	382	322	272	328
Total Operating Expenses	349	355	369	436	369	402	458	523	485	478	528
Selling, General & Admin Expense	160	155	160	198	163	167	185	191	147	145	174
Research & Development Expense	188	200	209	238	206	235	273	332	338	332	353
Total Other Income / (Expense), net	-1.97	-1.78	-8.07	-13	-7.37	-25	-25	7.19	14	11	13
Interest Expense	2.83	2.59	14	20	20	34	31	6.72	5.55	1.31	0.98
Interest & Investment Income	0.86	0.81	6.06	6.65	13	9.03	5.70	14	19	12	14
Income Tax Expense	0.68	3.00	30	-11	6.98	-15	13	38	7.94	36	7.00
Basic Earnings per Share	$0.70	$1.47	$1.11	$1.94	$0.44	$0.29	$49.44	$2.61	($1.09)	($5.93)	($1.98)
Weighted Average Basic Shares Outstanding	42.31M	41.71M	42.45M	43.16M	43.35M	43.78M	42.83M	35.09M	31.80M	32.19M	32.72M
Diluted Earnings per Share	$0.69	$1.45	$1.09	$1.90	$0.43	$0.28	$47.78	$2.54	($1.09)	($5.93)	($1.98)
Weighted Average Diluted Shares Outstanding	42.95M	42.38M	43.33M	44.04M	44.29M	44.37M	44.32M	36.04M	31.80M	32.19M	32.72M
Weighted Average Basic & Diluted Shares Outstanding	42.30M	41.80M	42.40M	557.30M	43.50M	43.93M	38.20M	31.90M	31.90M	32.46M	32.96M

This table shows Silicon Laboratories' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	4/5/2025	7/5/2025	10/4/2025	1/3/2026	4/4/2026
Net Income / (Loss) Attributable to Common Shareholders	10	-70	-57	-82	-29	-24	-30	-22	-9.94	-2.68	-16
Consolidated Net Income / (Loss)	10	-70	-57	-82	-29	-24	-30	-22	-9.94	-2.68	-16
Net Income / (Loss) Continuing Operations	10	-70	-57	-82	-29	-24	-30	-22	-9.94	-2.68	-16
Total Pre-Tax Income	14	-70	-57	-45	-26	-26	-29	-19	-9.52	-0.53	-14
Total Operating Income	12	-73	-59	-48	-30	-29	-32	-23	-12	-3.25	-17
Total Gross Profit	119	44	55	77	90	90	98	108	119	132	127
Total Revenue	204	87	106	145	166	166	178	193	206	208	214
Operating Revenue	204	87	106	145	166	166	178	193	206	208	214
Total Cost of Revenue	85	43	51	69	76	76	80	85	87	76	87
Operating Cost of Revenue	85	43	51	69	76	76	80	85	87	76	87
Total Operating Expenses	107	117	114	125	120	119	130	131	131	135	144
Selling, General & Admin Expense	28	34	34	39	37	36	42	43	44	46	55
Research & Development Expense	79	83	81	86	83	82	88	88	88	90	89
Total Other Income / (Expense), net	1.58	2.67	2.22	2.53	3.21	2.72	3.51	3.58	2.82	2.72	3.39
Interest Expense	1.36	0.94	0.51	0.26	0.28	0.26	0.28	0.25	0.23	0.21	0.23
Interest & Investment Income	2.94	3.61	2.73	2.79	3.49	2.98	3.79	3.83	3.05	2.93	3.63
Income Tax Expense	3.39	-16	-0.39	37	2.01	-2.09	1.90	2.53	0.41	2.15	2.21
Basic Earnings per Share	$0.33	($2.21)	($1.77)	($2.56)	($0.88)	($0.72)	($0.94)	($0.67)	($0.30)	($0.07)	($0.48)
Weighted Average Basic Shares Outstanding	31.80M	31.80M	31.91M	32.12M	32.31M	32.19M	32.47M	32.68M	32.84M	32.72M	32.96M
Diluted Earnings per Share	$0.32	($2.15)	($1.77)	($2.56)	($0.88)	($0.72)	($0.94)	($0.67)	($0.30)	($0.07)	($0.48)
Weighted Average Diluted Shares Outstanding	32.08M	31.80M	31.91M	32.12M	32.31M	32.19M	32.47M	32.68M	32.84M	32.72M	32.96M
Weighted Average Basic & Diluted Shares Outstanding	31.78M	31.90M	31.92M	32.29M	32.45M	32.46M	32.57M	32.82M	32.85M	32.96M	32.98M

This table details how cash moves in and out of Silicon Laboratories' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	1/2/2016	12/31/2016	12/30/2017	12/29/2018	12/28/2019	1/2/2021	1/1/2022	12/31/2022	12/30/2023	12/28/2024	1/3/2026
Net Change in Cash & Equivalents	-28	27	128	-72	30	-24	872	-575	-272	54	83
Net Cash From Operating Activities	105	129	190	174	22	-8.84	91	141	-30	-14	96
Net Cash From Continuing Operating Activities	105	129	190	174	22	-8.84	91	141	-30	-14	96
Net Income / (Loss) Continuing Operations	30	61	47	84	-103	-115	-58	91	-35	-191	-65
Consolidated Net Income / (Loss)	30	61	47	84	19	13	2,117	91	-35	-191	-65
Depreciation Expense	13	13	15	16	15	16	18	23	26	26	25
Amortization Expense	29	28	37	57	51	64	67	36	26	23	13
Non-Cash Adjustments To Reconcile Net Income	41	38	45	50	44	51	46	57	64	62	80
Changes in Operating Assets and Liabilities, net	-6.55	-11	46	-33	14	-25	17	-66	-112	67	42
Net Cash From Investing Activities	-49	-50	-374	-197	-103	-358	-477	241	470	113	-12
Net Cash From Continuing Investing Activities	-49	-50	-374	-197	-103	-358	-477	241	470	113	-12
Purchase of Property, Plant & Equipment	-18	-20	-17	-36	-23	-19	-30	-27	-23	-12	-34
Purchase of Investments	-107	-185	-636	-396	-425	-520	-1,542	-607	-103	-74	-35
Divestitures	-	-	-	-	-	-	-	0.00	0.00	12	0.00
Sale and/or Maturity of Investments	172	162	294	474	345	497	1,095	874	596	186	56
Other Investing Activities, net	-	-	-	-	-	-	-	-	0.00	0.00	0.58
Net Cash From Financing Activities	-84	-52	313	-49	-30	201	-1,299	-887	-712	-45	-1.07
Net Cash From Continuing Financing Activities	-84	-52	313	-49	-30	201	-1,299	-887	-712	-45	-1.07
Repayment of Debt	-95	-5.00	-83	0.00	-1.13	-625	-141	-0.02	-571	-45	0.00
Repurchase of Common Equity	-71	-41	0.00	-39	-27	-16	-1,150	-883	-217	-0.02	0.00
Issuance of Debt	81	0.00	400	0.00	0.00	845	0.00	0.00	80	0.00	0.00
Issuance of Common Equity	17	13	12	13	14	15	14	12	15	16	15
Other Financing Activities, net	-16	-20	-16	-23	-16	-18	-22	-15	-18	-16	-16
Cash Interest Paid	2.47	2.22	3.86	6.23	6.37	8.66	5.01	4.43	4.47	0.99	0.63
Cash Income Taxes Paid	2.16	11	8.93	21	10	7.22	266	132	32	19	11

This table details how cash moves in and out of Silicon Laboratories' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	4/5/2025	7/5/2025	10/4/2025	1/3/2026	4/4/2026
Net Change in Cash & Equivalents	-75	68	-36	49	62	-21	43	-10	27	23	19
Net Cash From Operating Activities	-33	19	-72	16	32	10	48	4.91	34	8.35	4.93
Net Cash From Continuing Operating Activities	-33	19	-72	16	32	10	48	4.91	34	8.35	4.93
Net Income / (Loss) Continuing Operations	10	-70	-57	-82	-29	-24	-30	-22	-9.94	-2.68	-16
Consolidated Net Income / (Loss)	10	-70	-57	-82	-29	-24	-30	-22	-9.94	-2.68	-16
Depreciation Expense	6.55	6.72	6.63	6.52	6.15	6.25	6.25	6.45	6.07	5.95	6.05
Amortization Expense	6.26	6.21	6.08	6.08	5.44	5.44	5.44	3.34	2.29	2.30	2.30
Non-Cash Adjustments To Reconcile Net Income	5.85	26	14	16	16	16	20	20	20	21	21
Changes in Operating Assets and Liabilities, net	-62	49	-42	70	33	6.12	47	-2.96	16	-18	-8.57
Net Cash From Investing Activities	10	43	81	40	30	-38	-3.90	-10	-6.75	8.78	15
Net Cash From Continuing Investing Activities	10	43	81	40	30	-38	-3.90	-10	-6.75	8.78	15
Purchase of Property, Plant & Equipment	-5.25	-3.87	-2.05	-3.53	-2.21	-3.96	-4.85	-8.70	-6.39	-14	-9.84
Purchase of Investments	-10	-12	-9.79	-7.91	-11	-45	-20	-13	-6.28	4.00	0.00
Sale and/or Maturity of Investments	26	59	81	51	43	11	21	11	5.93	18	23
Other Investing Activities, net	-	-	-	-	-	-	0.00	-	-	-	1.27
Net Cash From Financing Activities	-52	5.65	-46	-6.40	0.42	6.58	-0.96	-5.18	-0.63	5.69	-0.96
Net Cash From Continuing Financing Activities	-52	5.65	-46	-6.40	0.42	6.58	-0.96	-5.18	-0.63	5.69	-0.96
Other Financing Activities, net	-0.93	-0.95	-1.05	-14	-0.87	-0.36	-0.96	-13	-1.16	-0.80	-0.96

This table presents Silicon Laboratories' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	1/2/2016	12/31/2016	12/30/2017	12/29/2018	12/28/2019	1/2/2021	1/1/2022	12/31/2022	12/30/2023	12/28/2024	1/3/2026
Total Assets	1,011	1,082	1,535	1,624	1,675	1,993	2,958	2,169	1,443	1,223	1,269
Total Current Assets	423	491	948	827	944	976	2,239	1,461	738	602	674
Cash & Equivalents	114	141	269	197	227	203	1,075	500	228	282	364
Short-Term Investments	129	154	495	417	499	522	965	692	212	101	79
Accounts Receivable	74	74	71	73	76	95	98	71	29	54	65
Inventories, net	54	60	73	75	73	48	49	100	194	106	96
Prepaid Expenses	53	62	39	65	69	87	52	98	75	60	70
Plant, Property, & Equipment, net	131	130	128	139	136	136	147	152	146	132	129
Total Noncurrent Assets	457	461	460	659	595	882	573	556	559	489	467
Long-Term Investments	7.13	-	-	-	-	77	78	95	123	76	67
Goodwill	273	276	288	397	398	376	376	376	376	376	376
Intangible Assets	121	104	83	171	134	163	119	85	60	36	23
Total Liabilities & Shareholders' Equity	1,011	1,082	1,535	1,624	1,675	1,993	2,958	2,169	1,443	1,223	1,269
Total Liabilities	250	255	582	557	560	794	746	764	234	143	175
Total Current Liabilities	142	140	162	145	138	284	669	186	164	98	144
Accounts Payable	42	40	39	41	39	55	47	90	57	42	51
Current Deferred Revenue	35	46	50	22	19	13	14	6.78	2.12	3.07	5.36
Other Current Liabilities	-	55	73	81	80	82	157	89	59	52	88
Total Noncurrent Liabilities	108	115	420	412	422	509	77	579	71	45	31
Other Noncurrent Operating Liabilities	-	-	-	-	-	80	77	49	71	45	31
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	761	827	953	1,067	1,115	1,200	2,212	1,405	1,209	1,080	1,094
Total Preferred & Common Equity	761	827	953	1,067	1,115	1,200	2,212	1,405	1,209	1,080	1,094
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	761	827	953	1,067	1,115	1,200	2,212	1,405	1,209	1,080	1,094
Common Stock	14	24	103	108	134	204	0.00	0.00	17	78	157
Retained Earnings	748	802	851	961	981	994	2,215	1,416	1,193	1,002	937
Accumulated Other Comprehensive Income / (Loss)	-0.51	0.49	-1.16	-1.57	0.65	1.81	-2.42	-11	-1.03	0.07	0.20

This table presents Silicon Laboratories' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	10/1/2022	4/1/2023	7/1/2023	9/30/2023	3/30/2024	6/29/2024	9/28/2024	4/5/2025	7/5/2025	10/4/2025	4/4/2026
Total Assets	2,336	2,161	1,519	1,475	1,344	1,250	1,249	1,229	1,221	1,253	1,266
Total Current Assets	1,626	1,461	821	774	646	600	614	619	618	653	676
Cash & Equivalents	483	716	235	160	191	241	303	325	314	341	383
Short-Term Investments	893	436	271	257	141	98	67	100	101	98	56
Accounts Receivable	77	88	98	102	33	41	49	52	56	67	77
Inventories, net	88	133	146	168	198	166	139	83	81	82	103
Prepaid Expenses	84	88	71	87	83	54	56	58	65	64	57
Plant, Property, & Equipment, net	152	152	152	151	142	139	135	130	131	128	132
Total Noncurrent Assets	559	549	545	551	556	511	500	481	472	472	458
Long-Term Investments	91	94	97	109	126	87	81	74	68	70	61
Goodwill	376	376	376	376	376	376	376	376	376	376	376
Intangible Assets	92	78	72	66	53	47	42	31	28	25	21
Total Liabilities & Shareholders' Equity	2,336	2,161	1,519	1,475	1,344	1,250	1,249	1,229	1,221	1,253	1,266
Total Liabilities	785	742	260	215	179	157	168	161	160	182	168
Total Current Liabilities	206	693	219	165	111	100	118	120	121	145	132
Accounts Payable	82	71	55	48	45	39	45	54	58	56	56
Current Deferred Revenue	12	11	11	10	3.92	3.32	8.48	6.48	3.86	8.45	9.82
Other Current Liabilities	112	81	72	62	63	57	65	59	59	81	66
Total Noncurrent Liabilities	579	49	41	50	67	57	50	41	39	37	35
Other Noncurrent Operating Liabilities	50	49	41	50	67	57	50	41	39	37	35
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,552	1,419	1,259	1,260	1,166	1,093	1,081	1,068	1,061	1,071	1,099
Total Preferred & Common Equity	1,552	1,419	1,259	1,260	1,166	1,093	1,081	1,068	1,061	1,071	1,099
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,552	1,419	1,259	1,260	1,166	1,093	1,081	1,068	1,061	1,071	1,099
Common Stock	0.00	0.00	0.00	0.00	30	39	56	97	112	131	178
Retained Earnings	1,568	1,426	1,263	1,263	1,136	1,054	1,026	971	949	939	921
Accumulated Other Comprehensive Income / (Loss)	-16	-6.46	-4.09	-2.60	-0.48	-0.25	0.27	0.33	0.08	0.23	0.06

This table displays calculated financial ratios and metrics derived from Silicon Laboratories' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	1/2/2016	12/31/2016	12/30/2017	12/29/2018	12/28/2019	1/2/2021	1/1/2022	12/31/2022	12/30/2023	12/28/2024	1/3/2026
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	3.89%	8.19%	10.21%	12.93%	-45.43%	7.84%	41.09%	42.07%	-23.62%	-25.30%	34.29%
EBITDA Growth	-9.54%	45.11%	27.91%	15.30%	-114.06%	-20.64%	295.70%	238.87%	-84.32%	-519.21%	72.24%
EBIT Growth	-37.03%	105.61%	28.21%	0.28%	-204.03%	-20.81%	69.34%	463.18%	-120.25%	-585.15%	57.37%
NOPAT Growth	-20.95%	100.53%	-17.66%	89.69%	-162.86%	-20.81%	69.34%	461.07%	-120.37%	-585.15%	57.37%
Net Income Growth	-22.19%	107.85%	-23.42%	77.51%	-76.95%	-34.95%	16,797.29%	-95.68%	-137.76%	-453.40%	66.02%
EPS Growth	-20.69%	110.14%	-24.83%	74.31%	-77.37%	-34.88%	16,964.29%	-94.68%	-142.91%	-444.04%	66.61%
Operating Cash Flow Growth	-23.28%	22.25%	47.02%	-8.43%	-87.22%	-139.86%	1,131.77%	54.91%	-121.48%	54.17%	788.05%
Free Cash Flow Firm Growth	-152.61%	188.71%	100.23%	-275.09%	95.23%	891.99%	79.93%	-117.59%	-218.11%	21.98%	77.01%
Invested Capital Growth	15.07%	2.87%	-5.93%	42.21%	-6.30%	-16.61%	-19.29%	18.67%	6.68%	-9.97%	-6.20%
Revenue Q/Q Growth	-0.29%	3.34%	2.45%	1.70%	-43.17%	60.86%	28.46%	4.99%	-17.89%	15.72%	5.65%
EBITDA Q/Q Growth	-4.28%	15.24%	8.14%	-2.09%	-116.76%	76.02%	1,250.99%	8.25%	-77.76%	27.00%	40.32%
EBIT Q/Q Growth	-15.89%	29.98%	8.02%	-8.61%	-243.37%	41.65%	63.97%	21.91%	-133.07%	21.19%	26.46%
NOPAT Q/Q Growth	-12.66%	28.89%	-32.80%	37.43%	-307.78%	41.65%	63.97%	37.55%	-132.60%	21.19%	26.46%
Net Income Q/Q Growth	-12.86%	30.72%	-34.64%	31.44%	-21.99%	-5.77%	-0.57%	45.21%	-156.93%	19.40%	24.57%
EPS Q/Q Growth	-12.66%	29.46%	-34.73%	31.94%	-21.82%	-9.68%	0.19%	22.71%	-159.89%	19.43%	24.71%
Operating Cash Flow Q/Q Growth	-10.08%	3.42%	15.80%	-10.21%	-86.42%	90.42%	380.77%	-17.08%	13.36%	-152.82%	-1.82%
Free Cash Flow Firm Q/Q Growth	-50.44%	-13.41%	7.58%	16.59%	-110.10%	115.38%	-83.21%	89.87%	47.29%	-2,382.90%	-704.42%
Invested Capital Q/Q Growth	4.29%	7.84%	2.57%	1.25%	0.12%	-36.79%	49.10%	5.64%	-11.31%	-1.27%	3.98%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	59.05%	60.42%	59.07%	60.05%	59.14%	57.71%	59.01%	62.74%	58.88%	53.42%	58.23%
EBITDA Margin	11.46%	15.37%	17.84%	18.21%	-4.69%	-5.25%	7.28%	17.37%	3.56%	-20.00%	-4.14%
Operating Margin	5.00%	9.50%	11.05%	9.81%	-18.71%	-20.96%	-4.56%	11.65%	-3.09%	-28.32%	-8.99%
EBIT Margin	5.00%	9.50%	11.05%	9.81%	-18.71%	-20.96%	-4.56%	11.65%	-3.09%	-28.32%	-8.99%
Profit (Net Income) Margin	4.59%	8.81%	6.12%	9.63%	4.07%	2.45%	293.73%	8.93%	-4.41%	-32.69%	-8.27%
Tax Burden Percent	97.76%	95.35%	61.24%	115.84%	-20.07%	-9.48%	-3,639.71%	72.28%	327.38%	123.38%	112.08%
Interest Burden Percent	93.89%	97.31%	90.50%	84.69%	108.31%	123.45%	177.16%	106.03%	43.65%	93.55%	82.10%
Effective Tax Rate	2.24%	4.65%	38.76%	-15.84%	0.00%	0.00%	0.00%	30.41%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	5.36%	9.90%	8.29%	13.39%	-7.40%	-10.08%	-3.76%	13.90%	-2.53%	-17.64%	-8.19%
ROIC Less NNEP Spread (ROIC-NNEP)	6.48%	10.99%	10.17%	18.93%	-39.57%	-31.23%	-199.25%	13.21%	0.24%	-2.23%	-4.98%
Return on Net Nonoperating Assets (RNNOA)	-1.47%	-2.16%	-3.00%	-5.11%	9.17%	11.16%	127.87%	-8.85%	-0.12%	0.95%	2.22%
Return on Equity (ROE)	3.90%	7.74%	5.29%	8.28%	1.77%	1.08%	124.11%	5.05%	-2.64%	-16.69%	-5.97%
Cash Return on Invested Capital (CROIC)	-8.66%	7.07%	14.39%	-21.47%	-0.90%	8.03%	17.59%	-3.17%	-8.99%	-7.15%	-1.79%
Operating Return on Assets (OROA)	3.14%	6.33%	6.49%	5.39%	-5.37%	-5.84%	-1.33%	4.65%	-1.34%	-12.42%	-5.66%
Return on Assets (ROA)	2.88%	5.88%	3.60%	5.29%	1.17%	0.68%	85.52%	3.57%	-1.91%	-14.33%	-5.21%
Return on Common Equity (ROCE)	3.90%	7.74%	5.29%	8.28%	1.77%	1.08%	124.11%	5.05%	-2.64%	-16.69%	-5.97%
Return on Equity Simple (ROE_SIMPLE)	3.89%	7.44%	4.94%	7.83%	1.73%	1.04%	95.70%	6.51%	-2.86%	-17.69%	0.00%
Net Operating Profit after Tax (NOPAT)	32	63	52	99	-62	-75	-23	83	-17	-116	-49
NOPAT Margin	4.89%	9.06%	6.77%	11.37%	-13.10%	-14.67%	-3.19%	8.10%	-2.16%	-19.82%	-6.29%
Net Nonoperating Expense Percent (NNEP)	-1.12%	-1.09%	-1.89%	-5.54%	32.17%	21.15%	195.49%	0.69%	-2.76%	-15.41%	-3.21%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	4.29%	-1.35%	-10.73%	-4.51%
Cost of Revenue to Revenue	40.95%	39.58%	40.93%	39.95%	40.86%	42.29%	40.99%	37.26%	41.12%	46.58%	41.77%
SG&A Expenses to Revenue	24.89%	22.29%	20.77%	22.79%	34.44%	32.64%	25.67%	18.65%	18.79%	24.89%	22.21%
R&D to Revenue	29.16%	28.63%	27.25%	27.45%	43.41%	46.03%	37.90%	32.45%	43.18%	56.85%	45.01%
Operating Expenses to Revenue	54.05%	50.92%	48.02%	50.24%	77.85%	78.67%	63.57%	51.10%	61.97%	81.74%	67.22%
Earnings before Interest and Taxes (EBIT)	32	66	85	85	-89	-107	-33	119	-24	-165	-71
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	74	107	137	158	-22	-27	52	178	28	-117	-32
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.65	3.28	3.94	3.17	4.53	4.65	3.75	3.21	3.48	3.84	3.96
Price to Tangible Book Value (P/TBV)	5.50	6.07	6.46	6.79	8.68	8.46	4.83	4.78	5.44	6.22	6.24
Price to Revenue (P/Rev)	3.13	3.89	4.89	3.90	10.67	10.92	11.51	4.41	5.37	7.10	5.52
Price to Earnings (P/E)	68.21	44.13	79.81	40.52	262.33	445.37	3.92	49.40	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.47%	2.27%	1.25%	2.47%	0.38%	0.22%	25.52%	2.02%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.00	3.92	5.61	3.68	5.86	7.90	12.14	5.80	5.33	5.93	6.55
Enterprise Value to Revenue (EV/Rev)	2.92	3.63	4.44	3.67	10.03	10.46	9.20	3.67	4.71	6.31	4.87
Enterprise Value to EBITDA (EV/EBITDA)	25.53	23.63	24.90	20.15	0.00	0.00	126.30	21.13	132.17	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	58.51	38.23	40.18	37.39	0.00	0.00	0.00	31.51	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	59.85	40.10	65.61	32.27	0.00	0.00	0.00	45.28	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	17.89	19.66	18.02	18.36	214.19	0.00	72.69	26.60	0.00	0.00	39.95
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	56.13	37.78	0.00	0.00	89.43	61.66	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.16	0.14	0.44	0.39	0.38	0.47	0.20	0.38	0.04	0.00	0.00
Long-Term Debt to Equity	0.14	0.14	0.44	0.39	0.38	0.36	0.00	0.38	0.00	0.00	0.00
Financial Leverage	-0.23	-0.20	-0.29	-0.27	-0.23	-0.36	-0.64	-0.67	-0.49	-0.43	-0.45
Leverage Ratio	1.35	1.32	1.47	1.56	1.51	1.58	1.45	1.42	1.38	1.16	1.15
Compound Leverage Factor	1.27	1.28	1.33	1.32	1.64	1.96	2.57	1.50	0.60	1.09	0.94
Debt to Total Capital	13.43%	12.23%	30.58%	27.86%	27.46%	31.95%	16.92%	27.37%	3.59%	0.00%	0.00%
Short-Term Debt to Total Capital	1.14%	0.00%	0.00%	0.00%	0.00%	7.63%	16.92%	0.00%	3.59%	0.00%	0.00%
Long-Term Debt to Total Capital	12.29%	12.23%	30.58%	27.86%	27.46%	24.33%	0.00%	27.37%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	86.57%	87.77%	69.42%	72.14%	72.54%	68.05%	83.08%	72.63%	96.41%	100.00%	100.00%
Debt to EBITDA	1.60	1.07	3.06	2.61	-18.99	-21.01	8.59	2.98	1.61	0.00	0.00
Net Debt to EBITDA	-1.79	-1.68	-2.51	-1.28	13.67	8.87	-31.75	-4.26	-18.56	0.00	0.00
Long-Term Debt to EBITDA	1.46	1.07	3.06	2.61	-18.99	-15.99	0.00	2.98	0.00	0.00	0.00
Debt to NOPAT	3.75	1.82	8.07	4.18	-6.80	-7.52	-19.60	6.38	-2.66	0.00	0.00
Net Debt to NOPAT	-4.19	-2.85	-6.62	-2.04	4.90	3.17	72.50	-9.12	30.61	0.00	0.00
Long-Term Debt to NOPAT	3.43	1.82	8.07	4.18	-6.80	-5.72	0.00	6.38	0.00	0.00	0.00
Altman Z-Score	6.95	8.66	5.95	5.69	6.92	5.41	8.57	5.82	12.88	19.11	16.84
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.97	3.51	5.84	5.71	6.85	3.43	3.35	7.87	4.51	6.15	4.69
Quick Ratio	2.22	2.64	5.15	4.74	5.82	2.88	3.20	6.80	2.86	4.46	3.53
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-51	45	90	-158	-7.54	60	108	-19	-60	-47	-11
Operating Cash Flow to CapEx	596.86%	653.44%	1,101.10%	488.51%	95.48%	-45.80%	306.70%	532.61%	-133.09%	-118.40%	282.14%
Free Cash Flow to Firm to Interest Expense	-17.99	17.45	6.40	-8.04	-0.37	1.75	3.46	-2.81	-10.83	-35.83	-11.07
Operating Cash Flow to Interest Expense	37.29	49.83	13.41	8.81	1.10	-0.26	2.94	21.01	-5.46	-10.62	98.16
Operating Cash Flow Less CapEx to Interest Expense	31.04	42.20	12.20	7.01	-0.05	-0.82	1.98	17.07	-9.57	-19.59	63.37
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.63	0.67	0.59	0.55	0.29	0.28	0.29	0.40	0.43	0.44	0.63
Accounts Receivable Turnover	8.96	9.43	10.55	12.01	6.37	5.98	7.45	12.07	15.53	13.95	13.19
Inventory Turnover	4.96	4.87	4.74	4.68	2.62	3.57	6.08	5.10	2.18	1.82	3.26
Fixed Asset Turnover	4.89	5.35	5.98	6.51	3.45	3.76	5.11	6.86	5.25	4.20	6.02
Accounts Payable Turnover	6.52	6.76	8.02	8.67	4.84	4.61	5.78	5.56	4.37	5.45	7.04
Days Sales Outstanding (DSO)	40.75	38.72	34.60	30.39	57.33	61.01	48.98	30.25	23.50	26.16	27.67
Days Inventory Outstanding (DIO)	73.62	75.00	76.97	77.92	139.56	102.13	60.02	71.62	167.20	201.10	112.03
Days Payable Outstanding (DPO)	56.02	54.00	45.49	42.10	75.49	79.26	63.17	65.62	83.60	67.01	51.87
Cash Conversion Cycle (CCC)	58.35	59.71	66.08	66.21	121.40	83.87	45.83	36.25	107.10	160.25	87.83
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	629	647	609	866	811	676	546	648	691	622	584
Invested Capital Turnover	1.10	1.09	1.22	1.18	0.57	0.69	1.18	1.72	1.17	0.89	1.30
Increase / (Decrease) in Invested Capital	82	18	-38	257	-55	-135	-130	102	43	-69	-39
Enterprise Value (EV)	1,886	2,534	3,414	3,186	4,750	5,343	6,629	3,758	3,686	3,688	3,824
Market Capitalization	2,018	2,714	3,759	3,387	5,054	5,581	8,295	4,515	4,203	4,146	4,334
Book Value per Share	$18.31	$19.81	$22.39	$24.74	$25.71	$27.38	$55.05	$42.21	$38.03	$33.28	$33.31
Tangible Book Value per Share	$8.83	$10.71	$13.66	$11.57	$13.43	$15.06	$42.73	$28.35	$24.32	$20.56	$21.15
Total Capital	879	942	1,373	1,480	1,537	1,763	2,663	1,935	1,254	1,080	1,094
Total Debt	118	115	420	412	422	563	451	530	45	0.00	0.00
Total Long-Term Debt	108	115	420	412	422	429	0.00	530	0.00	0.00	0.00
Net Debt	-132	-180	-344	-202	-304	-238	-1,666	-757	-518	-458	-511
Capital Expenditures (CapEx)	18	20	17	36	23	19	30	27	23	12	34
Debt-free, Cash-free Net Working Capital (DFCFNWC)	48	56	21	68	80	101	-19	84	180	122	87
Debt-free Net Working Capital (DFNWC)	291	351	785	682	806	826	2,020	1,276	619	504	530
Net Working Capital (NWC)	281	351	785	682	806	691	1,570	1,276	574	504	530
Net Nonoperating Expense (NNE)	1.93	1.70	4.94	15	-81	-87	-2,140	-8.41	18	75	16
Net Nonoperating Obligations (NNO)	-132	-180	-344	-202	-304	-523	-1,666	-757	-518	-458	-511
Total Depreciation and Amortization (D&A)	42	41	52	73	66	80	85	59	52	49	38
Debt-free, Cash-free Net Working Capital to Revenue	7.42%	8.04%	2.77%	7.83%	16.92%	19.79%	-2.62%	8.17%	23.03%	20.87%	11.04%
Debt-free Net Working Capital to Revenue	45.10%	50.34%	102.14%	78.52%	170.15%	161.63%	280.27%	124.56%	79.18%	86.27%	67.57%
Net Working Capital to Revenue	43.55%	50.34%	102.14%	78.52%	170.15%	135.31%	217.76%	124.56%	73.42%	86.27%	67.57%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.70	$1.47	$1.11	$1.94	$0.44	$0.29	$49.44	$2.61	($1.09)	($5.93)	($1.98)
Adjusted Weighted Average Basic Shares Outstanding	42.31M	41.71M	42.45M	43.16M	43.35M	43.78M	42.83M	35.09M	31.80M	32.19M	32.72M
Adjusted Diluted Earnings per Share	$0.69	$1.45	$1.09	$1.90	$0.43	$0.28	$47.78	$2.54	($1.09)	($5.93)	($1.98)
Adjusted Weighted Average Diluted Shares Outstanding	42.95M	42.38M	43.33M	44.04M	44.29M	44.37M	44.32M	36.04M	31.80M	32.19M	32.72M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	41.55M	41.89M	42.71M	43.09M	43.50M	43.93M	38.20M	31.90M	31.90M	32.46M	32.96M
Normalized Net Operating Profit after Tax (NOPAT)	32	63	52	60	-62	-75	-23	83	-17	-116	-49
Normalized NOPAT Margin	4.89%	9.06%	6.77%	6.87%	-13.10%	-14.67%	-3.19%	8.10%	-2.16%	-19.82%	-6.29%
Pre Tax Income Margin	4.69%	9.25%	10.00%	8.31%	-20.26%	-25.88%	-8.07%	12.35%	-1.35%	-26.49%	-7.38%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	11.40	25.62	6.01	4.33	-4.38	-3.14	-1.06	17.74	-4.35	-126.33	-72.35
NOPAT to Interest Expense	11.14	24.43	3.68	5.01	-3.07	-2.20	-0.74	12.35	-3.04	-88.43	-50.64
EBIT Less CapEx to Interest Expense	5.15	17.99	4.80	2.52	-5.53	-3.70	-2.02	13.79	-8.45	-135.30	-107.14
NOPAT Less CapEx to Interest Expense	4.90	16.80	2.46	3.21	-4.21	-2.76	-1.70	8.40	-7.15	-97.40	-85.44
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	241.49%	65.93%	0.00%	46.99%	138.68%	129.97%	54.31%	966.53%	-629.09%	-0.01%	0.00%

This table displays calculated financial ratios and metrics derived from Silicon Laboratories' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	4/5/2025	7/5/2025	10/4/2025	1/3/2026	4/4/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	32,955,929.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	32,955,929.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-0.48
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-24.48%	-66.25%	-56.90%	-40.63%	-18.34%	91.43%	67.06%	32.66%	23.80%	25.24%	20.14%
EBITDA Growth	-44.15%	-261.18%	-241.35%	-217.28%	-172.41%	71.85%	56.07%	63.10%	78.04%	129.46%	57.15%
EBIT Growth	-59.58%	-403.68%	-402.12%	-379.73%	-343.17%	60.84%	45.75%	52.38%	58.46%	88.64%	46.75%
NOPAT Growth	-46.95%	-326.03%	-420.79%	-515.18%	-325.63%	60.84%	45.75%	52.38%	58.46%	88.64%	46.75%
Net Income Growth	-50.72%	-375.17%	-504.71%	-849.88%	-375.45%	65.86%	46.10%	73.44%	65.14%	88.73%	47.83%
EPS Growth	-46.67%	-382.89%	-531.71%	-875.76%	-375.00%	66.51%	46.89%	73.83%	65.91%	90.28%	48.94%
Operating Cash Flow Growth	-175.80%	33.76%	-440.66%	826.76%	194.73%	-45.36%	167.03%	-69.58%	8.52%	-17.56%	-89.75%
Free Cash Flow Firm Growth	31.75%	-19.13%	74.70%	122.68%	181.80%	151.74%	356.77%	108.35%	-52.99%	-25.69%	-135.48%
Invested Capital Growth	27.07%	6.68%	0.45%	-9.36%	-19.13%	-9.97%	-19.37%	-13.41%	-10.94%	-6.20%	5.02%
Revenue Q/Q Growth	-16.79%	-57.38%	22.49%	36.66%	14.47%	-0.09%	6.90%	8.51%	6.82%	1.07%	2.54%
EBITDA Q/Q Growth	-17.14%	-340.49%	22.87%	23.69%	48.84%	6.52%	-20.40%	35.91%	69.55%	225.38%	-275.15%
EBIT Q/Q Growth	-28.83%	-698.44%	19.12%	18.79%	38.14%	3.64%	-12.06%	28.72%	46.03%	73.65%	-425.28%
NOPAT Q/Q Growth	13.84%	-655.27%	19.12%	18.79%	38.14%	3.64%	-12.06%	28.72%	46.03%	73.65%	-425.28%
Net Income Q/Q Growth	-5.55%	-774.40%	19.00%	-45.34%	65.31%	16.42%	-27.90%	28.40%	54.46%	72.99%	-492.29%
EPS Q/Q Growth	-3.03%	-771.88%	17.67%	-44.63%	65.63%	18.18%	-30.56%	28.72%	55.22%	76.67%	-585.71%
Operating Cash Flow Q/Q Growth	-1,403.83%	155.52%	-487.33%	122.47%	96.03%	-67.97%	375.15%	-89.80%	599.31%	-75.67%	-40.91%
Free Cash Flow Firm Q/Q Growth	-0.85%	39.77%	52.81%	179.11%	263.74%	-61.90%	134.19%	-35.81%	-17.93%	-39.77%	-211.81%
Invested Capital Q/Q Growth	5.89%	-11.31%	2.27%	-5.62%	-5.52%	-1.27%	-8.40%	1.35%	-2.82%	3.98%	2.56%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	58.41%	50.58%	51.77%	52.68%	54.28%	54.27%	55.02%	56.06%	57.78%	63.44%	59.48%
EBITDA Margin	12.28%	-69.30%	-43.64%	-24.37%	-10.89%	-10.19%	-11.48%	-6.78%	-1.93%	2.40%	-4.09%
Operating Margin	6.00%	-84.19%	-55.59%	-33.03%	-17.85%	-17.22%	-18.05%	-11.86%	-5.99%	-1.56%	-8.00%
EBIT Margin	6.00%	-84.19%	-55.59%	-33.03%	-17.85%	-17.22%	-18.05%	-11.86%	-5.99%	-1.56%	-8.00%
Profit (Net Income) Margin	5.08%	-80.36%	-53.14%	-56.52%	-17.13%	-14.33%	-17.15%	-11.31%	-4.82%	-1.29%	-7.45%
Tax Burden Percent	75.01%	99.07%	99.32%	180.59%	107.57%	91.95%	106.65%	113.13%	104.35%	502.62%	116.14%
Interest Burden Percent	112.92%	96.35%	96.24%	94.74%	89.20%	90.51%	89.06%	84.34%	77.15%	16.42%	80.13%
Effective Tax Rate	24.56%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	6.19%	-68.85%	-35.41%	-17.88%	-8.96%	-10.73%	-12.98%	-9.38%	-5.23%	-1.42%	-7.87%
ROIC Less NNEP Spread (ROIC-NNEP)	6.03%	-65.93%	-32.84%	-7.65%	-7.30%	-9.95%	-11.30%	-8.10%	-4.96%	-1.34%	-7.08%
Return on Net Nonoperating Assets (RNNOA)	-3.04%	32.15%	14.92%	3.08%	2.91%	4.24%	4.84%	3.42%	2.21%	0.60%	3.26%
Return on Equity (ROE)	3.15%	-36.70%	-20.49%	-14.79%	-6.05%	-6.49%	-8.14%	-5.96%	-3.02%	-0.83%	-4.61%
Cash Return on Invested Capital (CROIC)	-16.39%	-8.99%	-10.66%	-6.95%	0.29%	-7.15%	6.26%	1.63%	0.30%	-1.79%	-11.56%
Operating Return on Assets (OROA)	3.00%	-36.46%	-20.36%	-12.94%	-6.62%	-7.55%	-9.20%	-6.75%	-3.56%	-0.98%	-5.26%
Return on Assets (ROA)	2.54%	-34.80%	-19.46%	-22.14%	-6.35%	-6.28%	-8.74%	-6.44%	-2.86%	-0.81%	-4.90%
Return on Common Equity (ROCE)	3.15%	-36.70%	-20.49%	-14.79%	-6.05%	-6.49%	-8.14%	-5.96%	-3.02%	-0.83%	-4.61%
Return on Equity Simple (ROE_SIMPLE)	4.81%	0.00%	-9.01%	-18.13%	-21.91%	0.00%	-15.44%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	9.22	-51	-41	-34	-21	-20	-22	-16	-8.64	-2.28	-12
NOPAT Margin	4.52%	-58.93%	-38.91%	-23.12%	-12.50%	-12.05%	-12.64%	-8.30%	-4.19%	-1.09%	-5.60%
Net Nonoperating Expense Percent (NNEP)	0.16%	-2.92%	-2.58%	-10.23%	-1.65%	-0.78%	-1.67%	-1.28%	-0.27%	-0.08%	-0.79%
Return On Investment Capital (ROIC_SIMPLE)	-	-4.08%	-	-	-	-1.86%	-2.10%	-1.51%	-0.81%	-0.21%	-1.09%
Cost of Revenue to Revenue	41.59%	49.42%	48.23%	47.32%	45.72%	45.73%	44.98%	43.94%	42.22%	36.56%	40.52%
SG&A Expenses to Revenue	13.63%	38.73%	31.54%	26.62%	22.11%	21.90%	23.43%	22.38%	21.20%	22.00%	25.99%
R&D to Revenue	38.79%	96.04%	75.82%	59.10%	50.02%	49.59%	49.64%	45.54%	42.57%	43.00%	41.50%
Operating Expenses to Revenue	52.42%	134.77%	107.36%	85.72%	72.13%	71.49%	73.07%	67.92%	63.77%	65.00%	67.48%
Earnings before Interest and Taxes (EBIT)	12	-73	-59	-48	-30	-29	-32	-23	-12	-3.25	-17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	25	-60	-46	-35	-18	-17	-20	-13	-3.98	4.99	-8.74
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.93	3.48	3.92	3.23	3.48	3.84	2.80	4.71	4.12	3.96	6.27
Price to Tangible Book Value (P/TBV)	4.52	5.44	6.21	5.28	5.67	6.22	4.52	7.61	6.59	6.24	9.83
Price to Revenue (P/Rev)	3.88	5.37	7.12	6.51	7.45	7.10	4.56	7.11	5.93	5.52	8.40
Price to Earnings (P/E)	60.90	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.64%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.12	5.33	5.81	4.66	5.25	5.93	4.37	7.82	6.94	6.55	10.68
Enterprise Value to Revenue (EV/Rev)	3.37	4.71	6.40	5.73	6.56	6.31	3.80	6.42	5.25	4.87	7.79
Enterprise Value to EBITDA (EV/EBITDA)	25.61	132.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	43.98	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	61.94	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	23.49	47.64	39.98	39.95	121.72
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	1,610.50	0.00	62.28	444.17	2,182.24	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.04	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.50	-0.49	-0.45	-0.40	-0.40	-0.43	-0.43	-0.42	-0.45	-0.45	-0.46
Leverage Ratio	1.36	1.38	1.36	1.18	1.16	1.16	1.15	1.15	1.16	1.15	1.15
Compound Leverage Factor	1.53	1.33	1.31	1.12	1.04	1.05	1.03	0.97	0.90	0.19	0.92
Debt to Total Capital	3.45%	3.59%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	3.45%	3.59%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	96.55%	96.41%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.36	1.61	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	-3.83	-18.56	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.87	-2.66	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	-9.27	30.61	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	12.67	12.77	17.34	15.47	15.40	19.48	13.17	20.84	16.59	17.01	26.76
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.68	4.51	5.80	5.99	5.19	6.15	5.17	5.12	4.49	4.69	5.11
Quick Ratio	3.14	2.86	3.28	3.80	3.54	4.46	3.98	3.91	3.48	3.53	3.89
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-157	-94	-45	35	128	49	114	73	60	36	-41
Operating Cash Flow to CapEx	-635.78%	478.50%	-3,507.57%	457.05%	1,432.38%	255.59%	991.92%	56.43%	536.87%	59.73%	50.16%
Free Cash Flow to Firm to Interest Expense	-115.36	-100.14	-87.56	134.05	461.30	187.94	402.93	292.66	266.76	169.67	-174.98
Operating Cash Flow to Interest Expense	-24.57	19.66	-141.06	61.35	113.77	38.96	169.46	19.55	151.87	39.02	21.27
Operating Cash Flow Less CapEx to Interest Expense	-28.43	15.55	-145.08	47.92	105.82	23.72	152.38	-15.10	123.58	-26.31	-21.13
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.50	0.43	0.37	0.39	0.37	0.44	0.51	0.57	0.59	0.63	0.66
Accounts Receivable Turnover	10.66	15.53	10.67	7.78	6.69	13.95	15.49	14.39	12.79	13.19	12.70
Inventory Turnover	2.96	2.18	1.69	1.59	1.56	1.82	2.14	2.57	2.96	3.26	3.58
Fixed Asset Turnover	6.30	5.25	4.36	3.72	3.53	4.20	4.82	5.20	5.64	6.02	6.28
Accounts Payable Turnover	5.84	4.37	4.83	5.25	5.16	5.45	6.11	6.50	6.53	7.04	6.07
Days Sales Outstanding (DSO)	34.25	23.50	34.21	46.93	54.58	26.16	23.57	25.36	28.55	27.67	28.73
Days Inventory Outstanding (DIO)	123.36	167.20	215.99	229.54	234.39	201.10	170.84	142.27	123.46	112.03	101.87
Days Payable Outstanding (DPO)	62.52	83.60	75.60	69.54	70.78	67.01	59.69	56.15	55.86	51.87	60.15
Cash Conversion Cycle (CCC)	95.09	107.10	174.60	206.93	218.18	160.25	134.71	111.48	96.15	87.83	70.45
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	779	691	707	667	630	622	570	578	561	584	599
Invested Capital Turnover	1.37	1.17	0.91	0.77	0.72	0.89	1.03	1.13	1.25	1.30	1.40
Increase / (Decrease) in Invested Capital	166	43	3.17	-69	-149	-69	-137	-89	-69	-39	29
Enterprise Value (EV)	3,212	3,686	4,109	3,106	3,312	3,688	2,490	4,516	3,897	3,824	6,392
Market Capitalization	3,693	4,203	4,567	3,532	3,763	4,146	2,989	4,999	4,406	4,334	6,892
Book Value per Share	$39.54	$38.03	$36.53	$34.24	$33.49	$33.28	$32.92	$32.58	$32.63	$33.31	$33.33
Tangible Book Value per Share	$25.66	$24.32	$23.06	$20.96	$20.54	$20.56	$20.36	$20.17	$20.38	$21.15	$21.28
Total Capital	1,305	1,254	1,166	1,093	1,081	1,080	1,068	1,061	1,071	1,094	1,099
Total Debt	45	45	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-481	-518	-459	-426	-451	-458	-498	-483	-509	-511	-500
Capital Expenditures (CapEx)	5.25	3.87	2.05	3.53	2.21	3.96	4.85	8.70	6.39	14	9.84
Debt-free, Cash-free Net Working Capital (DFCFNWC)	236	180	202	161	126	122	74	82	68	87	105
Debt-free Net Working Capital (DFNWC)	653	619	535	500	496	504	499	497	507	530	544
Net Working Capital (NWC)	608	574	535	500	496	504	499	497	507	530	544
Net Nonoperating Expense (NNE)	-1.13	19	15	49	7.71	3.78	8.01	5.81	1.30	0.41	3.94
Net Nonoperating Obligations (NNO)	-481	-518	-459	-426	-451	-458	-498	-483	-509	-511	-500
Total Depreciation and Amortization (D&A)	13	13	13	13	12	12	12	9.80	8.36	8.24	8.34
Debt-free, Cash-free Net Working Capital to Revenue	24.80%	23.03%	31.48%	29.64%	24.98%	20.87%	11.31%	11.59%	9.18%	11.04%	12.79%
Debt-free Net Working Capital to Revenue	68.58%	79.18%	83.32%	92.18%	98.19%	86.27%	76.09%	70.69%	68.29%	67.57%	66.28%
Net Working Capital to Revenue	63.86%	73.42%	83.32%	92.18%	98.19%	86.27%	76.09%	70.69%	68.29%	67.57%	66.28%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.33	($2.21)	($1.77)	($2.56)	($0.88)	($0.72)	($0.94)	($0.67)	($0.30)	($0.07)	($0.48)
Adjusted Weighted Average Basic Shares Outstanding	31.80M	31.80M	31.91M	32.12M	32.31M	32.19M	32.47M	32.68M	32.84M	32.72M	32.96M
Adjusted Diluted Earnings per Share	$0.32	($2.15)	($1.77)	($2.56)	($0.88)	($0.72)	($0.94)	($0.67)	($0.30)	($0.07)	($0.48)
Adjusted Weighted Average Diluted Shares Outstanding	32.08M	31.80M	31.91M	32.12M	32.31M	32.19M	32.47M	32.68M	32.84M	32.72M	32.96M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	31.78M	31.90M	31.92M	32.29M	32.45M	32.46M	32.57M	32.82M	32.85M	32.96M	32.98M
Normalized Net Operating Profit after Tax (NOPAT)	9.22	-51	-41	-34	-21	-20	-22	-16	-8.64	-2.28	-12
Normalized NOPAT Margin	4.52%	-58.93%	-38.91%	-23.12%	-12.50%	-12.05%	-12.64%	-8.30%	-4.19%	-1.09%	-5.60%
Pre Tax Income Margin	6.77%	-81.11%	-53.50%	-31.30%	-15.93%	-15.58%	-16.08%	-10.00%	-4.62%	-0.26%	-6.41%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	8.99	-77.53	-116.18	-182.59	-106.86	-110.10	-112.96	-91.10	-54.61	-15.20	-73.63
NOPAT to Interest Expense	6.78	-54.27	-81.32	-127.81	-74.80	-77.07	-79.07	-63.77	-38.23	-10.64	-51.54
EBIT Less CapEx to Interest Expense	5.13	-81.64	-120.20	-196.01	-114.81	-125.35	-130.04	-125.75	-82.90	-80.52	-116.03
NOPAT Less CapEx to Interest Expense	2.92	-58.38	-85.35	-141.23	-82.75	-92.32	-96.15	-98.42	-66.52	-75.96	-93.94
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	690.83%	-629.09%	-190.01%	-8.10%	0.00%	-0.01%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Here’s a concise, four-year read on Silicon Laboratories (SLAB), focusing on what the quarterly cash flow statements, income statements, and balance sheets show for retail investors. The bullets highlight the most material trends and what they might imply for the stock's risk/return profile.

Revenue growth and improved gross margin in 2025. Q4 2025 revenue was 208.206M, up from 166.249M in Q4 2024 and well above the 2023 trough. Gross profit in Q4 2025 was 132.078M on revenue of 208.206M, yielding a gross margin of about 63.5% versus roughly 54.3% in Q4 2024 and 50.6% in Q4 2023, indicating stronger pricing/product mix or efficiency.
Consistent positive operating cash flow in 2025. The company generated positive net cash from continuing operating activities in each quarter of 2025 (examples: Q1 ~4.8M, Q2 ~4.9M, Q3 ~34.3M, Q4 ~8.4M), underscoring improving cash generation even as reported net income remained negative.
Liquidity remains robust with a strong balance sheet. In the latest quarter, total current assets (~652.6M in Q3 2025) vs. current liabilities (~145.3M) implies a high current ratio and ample liquidity. Cash and equivalents stood around 341.4M, and there is no long-term debt in recent periods, supporting financial flexibility.
Healthy equity cushion and limited financial leverage. Total equity was about 1.07B in Q3 2025, with total assets near 1.25B and total liabilities around 182M, suggesting a solid equity base relative to liabilities.
Historic revenue volatility and cyclicality. Revenue has shown material swings across the four-year window (2022 high, 2023 notable weakness, with partial rebound in 2024–2025), indicating exposure to product cycles and market demand variability.
R&D and SG&A spend remain high relative to revenue. While gross margins have expanded, operating expenses (including R&D and SG&A) remain a sizable share of revenue, weighing on profitability.
Profitability remains under pressure despite cash flow strength. Despite improving cash flow and top-line momentum in portions of 2024–2025, net income and earnings per share (EPS) have been negative in most 2025 quarters, reflecting ongoing profitability headwinds.
Net income declined year-over-year in 2025 quarters. Each 2025 quarter shows a net income attributable to common shareholders in the red: Q1 -$30.47M, Q2 -$21.82M, Q3 -$9.94M, Q4 -$2.68M.
Earnings per share remained negative in 2025. Basic EPS and Diluted EPS were negative for all four 2025 quarters (e.g., Q4 2025 Basic EPS -0.07, Diluted EPS -0.07; Q1 -0.94, Q2 -0.67, Q3 -0.30).
Investing cash flows have been variable, with both outflows and inflows over 2024–2025. Investing activity showed notable outflows in several quarters (e.g., Q2 2025 net cash from investing activities around -$10.15M; Q3 2025 around -$6.75M), while some quarters posted inflows from investments or asset sales, highlighting a fluctuating investment cadence rather than a single trend.

05/20/26 10:03 AM ETAI Generated. May Contain Errors.

Silicon Laboratories Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Silicon Laboratories' financial year ends in January. Their financial year 2026 ended on January 3, 2026.

Over the last 10 years, Silicon Laboratories' net income changed from $29.59 million in 2015 to -$64.91 million in 2025, a change of -319.4%. See Silicon Laboratories' forecast for analyst expectations on what's next for the company.

Silicon Laboratories' total operating income in 2025 was -$70.54 million, based on the following breakdown:

Total Gross Profit: $456.98 million
Total Operating Expenses: $527.52 million

Over the last 10 years, Silicon Laboratories' total revenue changed from $644.83 million in 2015 to $784.76 million in 2025, a change of 21.7%.

Silicon Laboratories' total liabilities were at $174.90 million at the end of 2025, a 22.6% increase from 2024, and a 30.1% decrease since 2015.

In the past 10 years, Silicon Laboratories' cash and equivalents has ranged from $114.09 million in 2015 to $1.07 billion in 2021, and is currently $364.22 million as of their latest financial filing in 2025.

Over the last 10 years, Silicon Laboratories' book value per share changed from 18.31 in 2015 to 33.31 in 2025, a change of 82.0%.

Related Companies

Financial statements for NASDAQ:SLAB last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silicon Laboratories (SLAB) Financials

Financials Breakdown Chart

Key Financial Trends

Silicon Laboratories Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silicon Laboratories (SLAB) Financials

Annual Income Statements for Silicon Laboratories

Quarterly Income Statements for Silicon Laboratories

Annual Cash Flow Statements for Silicon Laboratories

Quarterly Cash Flow Statements for Silicon Laboratories

Annual Balance Sheets for Silicon Laboratories

Quarterly Balance Sheets for Silicon Laboratories

Annual Metrics And Ratios for Silicon Laboratories

Quarterly Metrics And Ratios for Silicon Laboratories

Financials Breakdown Chart

Key Financial Trends

Silicon Laboratories Financials - Frequently Asked Questions

When does Silicon Laboratories' fiscal year end?

How has Silicon Laboratories' net income changed over the last 10 years?

What is Silicon Laboratories' operating income?

How has Silicon Laboratories' revenue changed over the last 10 years?

How much debt does Silicon Laboratories have?

How much cash does Silicon Laboratories have?

How has Silicon Laboratories' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools